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Abstract
Background: Hypercortisolism as a sign of hypothamamus-pituitary-adrenocortical (HPA) axis
overactivity and sleep EEG changes are frequently observed in depression. Closely related to the
HPA axis is the renin-angiotensin-aldosterone system (RAAS) as 1. adrenocorticotropic hormone
(ACTH) is a common stimulus for cortisol and aldosterone, 2. cortisol release is suppressed by
mineralocorticoid receptor (MR) agonists 3. angiotensin II (ATII) releases CRH and vasopressin
from the hypothalamus. Furthermore renin and aldosterone secretion are synchronized to the
rapid eyed movement (REM)-nonREM cycle.
Methods:  Here we focus on the difference of sleep related activity of the RAAS between
depressed patients and healthy controls. We studied the nocturnal plasma concentration of ACTH,
cortisol, renin and aldosterone, and sleep EEG in 7 medication free patients with depression (1
male, 6 females, age: (mean +/-SD) 53.3 ± 14.4 yr.) and 7 age matched controls (2 males, 5 females,
age: 54.7 ± 19.5 yr.). After one night of accommodation a polysomnography was performed
between 23.00 h and 7.00 h. During examination nights blood samples were taken every 20 min
between 23.00 h and 7.00 h. Area under the curve (AUC) for the hormones separated for the
halves of the night (23.00 h to 3.00 h and 3.00 h to 7.00 h) were used for statistical analysis, with
analysis of co variance being performed with age as a covariate.
Results: No differences in ACTH and renin concentrations were found. For cortisol, a trend to
an increase was found in the first half of the night in patients compared to controls (p < 0.06).
Aldosterone was largely increased in the first (p < 0.05) and second (p < 0.01) half of the night.
Cross correlations between hormone concentrations revealed that in contrast to earlier findings,
which included only male subjects, in our primarily female sample, renin and aldosterone secretion
were not coupled and no difference between patients and controls could be found, suggesting a
gender difference in RAAS regulation. No difference in conventional sleep EEG parameters were
found in our sample.
Conclusion: Hyperaldosteronism could be a sensitive marker for depression. Further our findings
point to an altered renal mineralocorticoid sensitivity in patients with depression.
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Background
Hypercortisolism as well as a reduced feedback inhibition
of the hypothalamus-pituitary-adrenocortical (HPA) sys-
tem are frequently observed in depression [1–3]. Further,
a decreased ability of dexamethasone to suppress adreno-
corticotropic hormone (ACTH) and cortisol secretion is
found in depressed patients, but appears to depend on the
clinical characteristics, especially "typical" vegetative
signs, as sleep disturbances and weight loss [4–8] and
reproductive state in females [9].
It has been suggested that the pathophysiology of the
hypercortisolism is related to a change in function of min-
eralocorticoid receptors (MR) (for review see [10], as a
block of the MR leads to hypercortisolism in healthy con-
trols [11,12]. However, the MR antagonist spironolacton
leads to an even more pronounced activation of the HPA
axis in depressed patients compared to controls [12],
showing that the MR itself is functionally intact in
depression.
The natural ligand of MR is aldosterone. The peripheral
concentration of aldosterone is regulated by the renin-
angiotensin-aldosterone system (RAAS). Several links
between the regulation of RAAS and the HPA system exist.
1. ACTH is a common stimulus for cortisol, but also for
aldosterone at the adrenal cortex [13]. 2. Spironolactone,
an MR antagonist, increases the cortisol concentration in
humans [14,15] and another MR antagonist, canrenoate,
reduces the sleep related inhibition of ACTH release
induced by an intravenous bolus of CRH [16]. These find-
ings suggest an activating action of MR blockade on HPA
system. The aldosterone agonist deoxicorticosterone
accordingly suppresses plasma cortisol in humans [17] 3.
Angiotensin II (AT II) has a direct stimulating action on
CRH and vasopressin release from the hypothalamus
[18,19]. 4. A polymorphism in the angiotensin converting
enzyme gene seems to be related to HPA axis changes in
depression [20].
What kind of change of the RAAS can be expected in
depression? Several possibilities might be assumed. 1. As
a consequence of the regulation of aldosterone by the
HPA axis, the impact of ACTH on the secretion of aldos-
terone could increase, leading to a higher coupling of
these hormones and a higher aldosterone concentration.
2. The activity of the RAAS and the strength of the cou-
pling of aldosterone to renin were increased during sleep
compared to wakefulness [21], i.e. it seems to be depend-
ent on arousal. As depression is accompanied by sleep dis-
turbances and can be viewed as a state of overarousal [22],
it might be suggested that the activity of the RAAS and the
strength of its coupling is weaker in depression. 3.
Changes in mineral metabolism have been reported in
depression [23,24]. An increase of plasma Mg2+ concen-
tration seems especially to be a trade marker in patients
with depression [25], plasma Na+ concentrations seem to
be unaffected by depression [26,27], whereas plasma K+
has been reported to be either unaffected [27] or
decreased [26]. One study showed a correlation between
serum cortisol and serum Mg2+ [26], which points again to
a close connection between the HPA-axis and the RAAS.
As aldosterone leads to an excretion of Mg2+ [28,29], a
decrease in aldosterone concentration or, alternatively,
sensitivity can be assumed.
Early studies showed a reduced plasma renin activity
(PRA) in depressed patients [30] and an increase in resting
PRA accompanied by a blunted renin response to posture
in bipolar patients [31]. The latter study described a nor-
mal aldosterone concentration, which was interpreted to
be inappropriately low in relation to the increased PRA. A
possible link between possible changes of the RAAS and
the HPA system in depression was further demonstrated
by the significant increase in aldosterone secretion after
administration of the glucocorticoid receptor agonist dex-
amethasone in healthy female subjects, whereas in
depressed females aldosterone showed a trend to a
decrease [32]. The latter finding could be a hint for an
increased coupling of aldosterone to ACTH in depression.
Besides endocrine changes, sleep is markedly changed in
depression [33–35]. A bidirectional interaction exists
between sleep and endocrine systems, especially the
RAAS. Renin and aldosterone secretion increase during
sleep and are synchronized to the nonREM-REM cycle
[36,37]. On the other hand the aldosterone antagonist
canrenoate reduced slow wave sleep (SWS) [16], whereas
the MR agonist deoxicorticosterone did not influence
sleep when given shortly before sleep onset [17].
In order to test the hypothesis of a decreased coupling of
the RAAS and a higher impact of the HPA axis on aldoster-
one secretion, we examined RAAS in connection with
HPA system activation and sleep EEG in depressed
patients compared to controls.
Methods
Subjects
We studied nocturnal plasma concentration and sleep
EEG in 7 patients with depression (1 male, 6 females, age:
53.3 ± 14.4 (mean ± SD), range 34 – 70 years) and 7 age
matched controls (2 males, 5 females, age: 54.7 ± 19.5,
range 27 – 76 years). The data from three of the controls
were derived from the control condition of an earlier
study [38] and four were newly recruited. Both patients
and controls were free of medication for at least 10 days
and for fluoxetine for at least 4 weeks with the exception
of 1 patient receiving 500 mg chloral hydrate at the two
study nights and one subject receiving metoclopramid 10BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/15
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mg once at the day of the examination. However, even
after exclusion of these subjects the main findings of the
study were unchanged (data not shown). No substances
for blood pressure regulation, especially beta-receptor
blockers or angiotensin-converting enzyme inhibitors or
diuretics were used by any of the subjects. Further no rel-
evant co morbidity, especially no cardiovascular, renal or
hepatic disorder was present in the patients or controls, as
assessed by clinical examination and a standard clinical
laboratory examination including serum creatinine and
liver enzyme levels. The personal and family history of the
controls was free of psychiatric disorders. Furthermore a
major life event was also ruled out in the controls. The
depressed patients were diagnosed according to DSM IV
criteria. Patient did not differ in body mass index (24.6 ±
2.7 for the controls vs. 24.6 ± 4.5 for the patients, n.s.).
Further characteristics are given in Table 1.
The study was approved by the Ethics committee of the
University of Munich and was performed according to the
Declaration of Helsinki in its version of Edinburgh, 2000.
Written informed consent has been obtained from each
participant before enrolment into the study.
Sleep and endocrine registration
The first study period consisted of an adaptation night,
when EEG electrodes were attached without recording an
EEG, followed by the examination night. For this the sub-
jects arrived at the sleep laboratory at 19.00 h. An intrave-
nous catheter was fixed at 19.30 h in the forearm, which
was connected via a tube through the wall with the adja-
cent room. Therefore, it was possible to get blood samples
without relevant disturbance of the subjects. The venous
catheter was perfused with 0.9% saline containing 200 I.E.
heparin per liter to keep the catheter patent in a constant
rate of 30 ml per hour. Hormone samples were collected
every 30 minutes between 20.00 h and 22.00 h and every
20 minutes between 22.00 h and 7.00 h. The first 5 ml
drawn from the catheter were removed and the subse-
quent 10 ml used for analysis. Blood was centrifuged
immediately after it was taken and the serum distributed
in 3 containers, which were immediately frozen at -20°C
for the rest of examination night and stored in a -80°C
freezer by the next morning. The hormone analysis took
place between 3 and 6 month after the examination. Only
the data for the duration between 23.00 h and 7.00 h were
used for analysis. The earlier data served as a control for
the stress reaction by administering the catheter.
Before lights out the subjects were allowed to read or
spoke with the technicians and were observed via video
monitoring. After 22.00 h the subjects stayed in bed aside
from rest room visits. The light was turned off at 23.00 h
and the subjects were allowed to sleep until 7.00 h. At this
time a polysomnography was performed.
Hormone analysis
The analysis of the serum levels cortisol, ACTH, renin and
aldosterone were done by radio immunoassay with a coef-
ficient of variation < 10 % for each hormone. The used
Table 1: Patients characteristics: (MDE: major depressive episode)
pat. sex age diagnosis
(DSM IV)
episode-
duration
history family 
history
sleep-disorder appetite mood-
reagibility
1 male 57 296.32
recurrent MDE, moderate
6 month 4th episode + early and middle 
insomnia
normal yes
2 female 38 296.33
recurrent MDE, severe, 
without psychotic symptoms
6 weeks multiple 
episodes
- early and middle 
insomnia
reduced yes
3 female 47 296.24
MDE severe, with psychotic 
symptoms
6 month 2nd episode - early, middle 
and late 
insomnia
10 kg weight 
loss
no
4 female 63 296.33
recurrent MDE severe, 
without psychotic symptoms
6 month 3rd episode + none 5 kg weight 
loss
yes
5 female 60 296.33
recurrent MDE severe, 
without psychotic symptoms
6 month multiple 
episodes
+ none reduced no
6 female 32 296.53
bipolar disorder, currently 
severe depression
12 month multiple 
depressive 
episodes, one 
manic episode
- hypersomnia reduced yes
7 female 47 296.33
recurrent MDE, severe 
without psychotic symptoms
6 month several 
episodes
+ early and middle 
insomnia
10 kg weight 
gain
noBMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/15
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kits were commercial radioimmunoassays for ACTH,
renin and angiotensin II provided by Nichols Institute
Diagnostics, San Juan Capistrano, USA, and for aldoster-
one and cortisol by DRG Instruments GmbH, Marburg,
Germany. All assays had a coefficient of variation of < 10
%. From the hormone concentrations the values for the
area under the curve (AUC) were calculated using the trap-
ezoid rule for the first half of the night (0 – 240 min) and
the second half of the night (240 – 480 min).
Sleep EEG analysis
Sleep recordings comprised two EEGs (C3-A2, C4-A1;
time constant 0.3 s, low-pass filtering 70 Hz), vertical and
horizontal electrooculograms, an electromyogram, and
an electrocardiogram. The electrooculogram, EEG, and
electromyogram signals were filtered (EEG: high pass 0.53
Hz, -3 dB; low pass 70 Hz, -3 dB; -12 dB octave, band-stop
between 42 and 62 Hz, -3 dB) and transmitted by an opti-
cal fiber system to the polygraph (Schwartzer, ED 24).
Sleep EEGs were rated visually according to standard crite-
ria [39] by an experienced rater who was blind to the study
protocol. Sleep EEG parameters used for the analysis were
the following: sleep onset latency [sleep onset defined as
the interval between light out and the first epoch of 30 s
containing stages 2, 3, 4, or REM sleep (min)]; total sleep
time (min); time spent in each of the following sleep
stages during time in bed (min): wake after sleep onset
(WASO), stage 2, SWS (non-REM stages 3 and 4), and
REM; REM latency [interval from sleep onset until the first
epoch containing stage REM (min)]; REM density (rapid
eye movement density, defined as the average number of
3-s mini-epochs of REM sleep including REMs per minute
of REM sleep).
Statistical analysis
Statistical analysis was performed using a personal com-
puter. The program for the statistical analysis was SPSS
version 9 for Windows. Multivariate analysis of covari-
ance was performed, taking age into account as a covari-
ate. Because of the low number of subjects and the pilot
character of this study we only present the univariate data,
and have not corrected the significance level for multiple
measurements. For the hormones the data were divided
into the first (23.00 – 3.00 h) and second (3.00 h – 7.00
h) half of the night.
To describe possible changes in the regulatory pathways
of the hormones we calculated the cross correlation
between ACTH, aldosterone and cortisol as well as that of
renin and aldosterone. For this analysis the "Cross corre-
lation" function of SPSS was used. As the maximal cross
correlations were generally found without time lack and
no systematic shift could be observed, we only describe
the results for this condition. The resulting figures repre-
sent the two tailed Pearson Correlation (see figure 1).
All values are expressed as mean ± standard deviation
(SD), when not otherwise stated. A significance level of p
< 0.05 is considered of being significant, data with p < 0.1
are presented and considered as trends.
Results
Depressed patients compared to controls did not show
any univariate difference of the sleep EEG parameters
compared to controls (Table 2). The same is true for the
parameters of the first and the second half of the night
(data not shown). Four of the patients and 2 of the con-
trols had to interrupt the bed rest due to rest room visits,
which took between 2.5 and 8 minutes.
Concerning endocrine parameters, for the first half of the
night there was a trend to an increase in cortisol (p < 0.06)
and a significant increase in aldosterone (p < 0.05), but no
change in ACTH or renin secretion. In the second half of
the night, a pronounced increase in aldosterone occurred
(p < 0.01), but no significant change in the other hor-
mones (Table 3). This endocrine change was not accom-
panied by changes in serum electrolyte concentrations
assessed some days before the sleep-endocrine examina-
tion (mmol/l): controls (n = 5) vs. depressed patients (n =
7): Na+: 140.6 ± 2.4 vs. 139.9 ± 2.5, (n.s.); K+: 4.02 ± 0.08
vs. 4.04 ± 0.37, (n.s.); Mg2+: 0.80 ± 0.09 vs. 0.84 ± 0.06
(n.s.).
To test the hypothesis that aldosterone release might be
primarily regulated by ACTH in depression and by renin
in controls, we calculated the cross correlation between
the various hormone concentrations. We found high cor-
relation coefficients between ACTH and cortisol, ACTH
and aldosterone, and between aldosterone and cortisol in
both depressed patients and controls. No difference
between depressed patients and controls was observed
(Table 4). Remarkable is the low correlation between
renin and aldosterone, both in depressed patients and in
controls, which suggests that during sleep ACTH is the pri-
mary trigger hormone for aldosterone in our population.
Discussion
The main new findings of this study are the huge increase
in aldosterone in depressed subjects compared to controls
and the unchanged cross correlation between the time
course of nocturnal hormone secretion, especially
between ACTH with cortisol and aldosterone and the lack
of a correlation between renin and aldosterone independ-
ent of presence or absence of depression.
A difference in the regulation of aldosterone in depressed
patients compared to controls has been described earlier:
Aldosterone increases in response to dexamethasone in
controls and shows a trend to a decrease in depressed sub-
jects [40]. Changes in plasma renin described previouslyBMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/15
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Time coures of nocturnal hormone secretion in patients with depression compared to controls (mean ± SEM) Figure 1
Time coures of nocturnal hormone secretion in patients with depression compared to controls (mean ± SEM). Cortisol is 
increased by trend in patients with depression compared to controls in the first half of the night (23.00 h – 3. 00 h) whereas 
aldosterone is significantly increased in the first and second half of the night. ACTH and renin show no difference.
Table 2: Comparison of selected sleep parameters: the parameters are based on time in bed (TIB), between controls and depressed 
patients (REM: rapid eye movement, REM-dens: REM-density, S2: stage 2, SOL: sleep onset latency, SWS: slow wave sleep, WASO: 
Wake after sleep onset).
depressed patients controls significance
TIB (min) 479.2 ± 2.6 481.1 ± 4.3 n.s.
SOL (min) 15.7 ± 11.5 26.4 ± 25.0 n.s.
REM latency (min) 97.3 ± 128.0 115.4 ± 90.0 n.s.
REM dens. (min-1) 4.45 ± 1.66 4.46 ± 1.73 n.s.
REM (min) 92.0 ± 46.2 77.9 ± 33.3 n.s.
S2 (min) 202.6 ± 39.2 216.9 ± 59.0 n.s.
SWS (min) 17.1 ± 12.7 34.1 ± 31.3 n.s.
WASO (min) 91.4 ± 69.7 73.7 ± 79.8 n.s.
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[30] differed from our findings, possibly because of meth-
odological differences, as we did not measure plasma
renin activity but plasma renin concentration. Further, we
could not find a positive cross correlation between renin
and aldosterone as described earlier in healthy male sub-
jects [37,41] and therefore could not find the expected dif-
ference in coupling of the RAAS in patients with
depression compared to control.
Our data have some important limitations with regard to
a general characteristic of depression. The number of
patients and controls is small and consists mainly of
female subjects. Typical sleep EEG changes as well as a
pronounced hypercortisolism, characteristics, which have
been described earlier, are missing in our populations.
This might partially be due to the fact that female patients,
which were the majority of our subjects, especially when
premenopausal, often do not show changes classically
described [9,33,42], although REM sleep changes seem to
be unaffected by gender [33,43]. Therefore two possibili-
ties arise from our findings. Firstly, the hyperaldos-
teronism is a more sensitive characteristic of depression
compared to hypercortisolism and the classical sleep EEG
findings of depressed patients, or alternatively, hyperal-
dosteronism is only a feature of depressed patients with
certain characteristics, i.e. female gender and possibly cer-
tain psychopathological signs, as described for example in
atypical depressive disorders [8,15,44]. However, we have
no evidence for a high prevalence of atypical depressive
features and especially not atypical vegetative features as
hypersomnia and hyperphagia in our population. In fact,
5 of the patients reported a decreased appetite at the
beginning of the hospitalisation. For the cross correla-
tional data, especially for the RAAS, it might be insuffi-
cient to have measurements every 20 minutes as the sharp
pulses of RAAS hormones could not be detected. This
might also be an explanation for the missing cross corre-
lation between renin and aldosterone, which has been
described for controls [37]. Another explanation for this
finding could also be a gender difference as the earlier
studies [37,41] examined exclusively males, whereas our
population consisted primarily of females. Such gender
differences for the temporal pattern of secretion have been
described for cortisol and growth hormone secretion [45]
and can be suggested for the RAAS by findings of the influ-
ence of sex steroids and gender on its regulation [46]. Fur-
thermore, several other factors might have influenced the
results as the climatic conditions, the ambient tempera-
ture and the light conditions, which have not been specif-
ically controlled for. As the patients and controls were
examined in the same standardized sleep laboratories a
major influence from these factors seems unlikely. Further
Table 3: Comparison of hormone parameters:AUC for the first (23.00 h – 3.00 h) and second (3.00 h – 7.00 h) half of the night.
depressed patients AUC controls AUC significance
1. half
ACTH (pg/ml × min) 3180 ± 1608 3193 ± 1074 n.s.
cortisol (ng/ml × min) 23690 ± 15330 11002 ± 4945 (n.s) p = 0.06
renin (pg/ml × min) 1656 ± 1000 1359 ± 249 n.s.
aldosterone (pg/ml × min) 9370 ± 5404 2914 ± 2932 p = 0.022
2. half
ACTH (pg/ml × min) 5601 ± 1741 6807 ± 2452 n.s.
cortisol (ng/ml × min) 45682 ± 17309 33395 ± 8991 n.s.
renin (pg/ml × min) 1588 ± 919 1504 ± 433 n.s.
aldosterone (pg/ml × min) 16075 ± 5908 6799 ± 4469 p = 0.009
Table 4: Crosscorrelation between hormone concentrations (23.00 h – 7.00 h):
depressed patients correlation 
coefficient
controls correlation coefficient significance
ACTH-cortisol 0.76 ± 0.10 0.79 ± 0.18 n.s.
ACTH-aldosterone 0.65 ± 0.23 0.58 ± 0.32 n.s.
renin-aldosterone 0.07 ± 0.33 0.17 ± 0.18 n.s.
ACTH-renin 0.00 ± 0.28 0.06 ± 0.38 n.s.
renin-cortisol -0.05 ± 0.37 0.04 ± 0.39 n.s.
aldosterone-cortisol 0.68 ± 0.29 0.63 ± 0.28 n.s.BMC Psychiatry 2003, 3 http://www.biomedcentral.com/1471-244X/3/15
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the food and fluid intake of the patients were not control-
led. The controls used their normal diet. This ensured, that
no adaptive changes to a standardized died occurred. As
the patients were hospitalized on a psychiatric ward, a
major deprivation of food and fluid can be ruled out.
Several possibilities exist for the mechanism of increased
aldosterone concentration. As neither renin nor ACTH,
the main releasing hormones for aldosterone, are
increased other factors seem to be responsible. Two possi-
bilities should be discussed here. 1. There is an influence
of the sympathetic system which could directly interact
with aldosterone secretion from the adrenal gland,
although renin release is also regulated by this system via
β-adrenoreceptors [47], stimulating its gene expression.
Therefore, it is unlikely that changes in the sympathetic
system alone contribute to the increase in aldosterone.
However, the unchanged renin levels were rather unex-
pected, since an overactivity of sympathetic system has
been shown in depressive disorder (for review see [48]).
As aldosterone release is stimulated, whereas renin release
is suppressed via a feedback inhibition by ATII [49], the
increase in aldosterone release together with an
unchanged renin level could be due to an increased ATII
activity, either by an increased concentration or an
increased functional activity at the receptor. Unfortu-
nately we have not measured the concentration of ATII
and therefore a level of uncertainty exists with this inter-
pretation. Other functional systems involved in aldoster-
one release, which have been reported to be changed in
depression include arginin vasopressin [50,51] and pros-
taglandins, especially prostaglandin E2 [52–54].
Despite the hyperaldosteronism no changes in electrolyte
concentrations could be found in this study. The only reli-
able finding in the literature of a change of electrolyte lev-
els in depression seems to be an increase in serum Mg2+.
As Mg2+ secretion is enhanced by aldosterone, these find-
ings together with the results of the present study suggest
an altered renal MR sensitivity in depression.
How this finding is related to the hypothesis of an altered
MR function is unclear, especially as the recent findings by
Young et al [12] question its validity. One important
aspect of these experiments is the use of spironolacton as
a ligand. The action of spironolacton differs from the nat-
ural ligand aldosterone, as the main metabolite of the
former, canrenone, seems not to be a substrate of the
multidrug resistance gene product p-glycoprotein as it
passes the blood brain barrier easily [55], whereas aldos-
terone is hampered by this enzyme to reach the intracere-
bral space [56]. P-glycoprotein has recently been
discussed to be involved in the neuroendocrine changes
in depression [57] and the effect of antidepressant sub-
stances [54,58]. Our present data in connection to those
of Young et al. [12] are in line with this hypothesis. It is
further supported by the finding, that aldosterone release
by human adrenal cells is increased by increased p-glyco-
protein activity [59].
Conclusion
In conclusion our preliminary findings point to the possi-
ble involvement of the renin-angiotensin-aldosterone sys-
tem in affective disorders. By comparing our findings with
the literature a gender difference in the regulation of the
RAAS is suggested. Further the data provide evidence for
an altered renal MR sensitivity in depression. Finally, as
hyperactivity of the RAAS is linked to altered cardiovascu-
lar regulation our findings contribute to explain the
increased risk for cardiovascular diseases observed in
affective disorders [60,61].
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